Lv2
126 积分 2025-03-06 加入
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
4小时前
待确认
FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell-Mediated Bladder Cancer Immune Surveillance
14天前
已完结
Bruceine A inhibits TGF-β1/Smad pathway in pulmonary fibrosis by blocking gal3/TGF-β1 interaction
24天前
已完结
Baicalein tethers CD274/PD-L1 for autophagic degradation to boost antitumor immunity
1个月前
已完结
AMPK: Balancing mitochondrial quality and quantity through opposite regulation of mitophagy pathways
1个月前
已完结
LRP1 induces anti-PD-1 resistance by modulating the DLL4-NOTCH2-CCL2 axis and redirecting M2-like macrophage polarisation in bladder cancer
1个月前
已完结
Novel therapeutic strategies: targeting epithelial–mesenchymal transition in colorectal cancer
1个月前
已完结
Tumor Immune Microenvironment during Epithelial-Mesenchymal Transition
1个月前
已完结
β-Arbutin and cisplatin: A combined approach to modulating apoptosis, cell viability, and migration in bladder cancer cells
1个月前
已完结
Synergic effects of DL-limonene, R-limonene, and cisplatin on AKT, PI3K, and mTOR gene expression in MDA-MB-231 and 5637 cell lines
1个月前
已完结
皖公网安备34019202002308
